Ikarian Capital, LLC historic quarter change: USA Options, Reduced
In put and call options, at their filed underlying value (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Ikarian Capital, LLC opened 248 positions, added to 64, reduced 62 and sold out of 276.
- Q2 2026: Stock BMY; Country of operation United States; Class COM · Put; Shares before 500,000.
- Q2 2026: Stock OLMA; Country of operation United States; Class COM · Call; Shares before 549,800.
- Q2 2026: Stock UNIQURE NV; Country of operation —; Class CALL · Call; Shares before 355,000.
- Q1 2026: Stock XBI; Country of operation —; Class STATE STREET SPD · Put; Shares before 850,000.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1778253), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-18); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-17). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2019-12-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q2 2026 | BMY
BRISTOL-MYERS SQUIBB CO | United States | COM · Put | 500,000 | 42,500 | -457,500 | $30,325,000 | $2,448,850 | -$27,876,150 | 2026-08-14 |
|---|
| Q2 2026 | OLMA
OLEMA PHARMACEUTICALS INC | United States | COM · Call | 549,800 | 200,000 | -349,800 | $8,197,518 | $2,502,000 | -$5,695,518 | 2026-08-14 |
|---|
| Q2 2026 | UNIQURE NV
CUSIP N90064901 | | CALL · Call | 355,000 | 49,800 | -305,200 | $5,804,250 | $2,293,788 | -$3,510,462 | 2026-08-14 |
|---|
| Q1 2026 | XBI
SPDR SERIES TRUST | | STATE STREET SPD · Put | 850,000 | 800,000 | -50,000 | $103,640,500 | $102,184,000 | -$1,456,500 | 2026-05-15 |
|---|
| Q4 2025 | UNIQURE NV
CUSIP N90064901 | | CALL · Call | 535,600 | 105,400 | -430,200 | $31,262,972 | $2,522,222 | -$28,740,750 | 2026-02-18 |
|---|
| Q4 2025 | INSM
INSMED INC | United States | COM PAR $.01 · Call | 100,000 | 8,600 | -91,400 | $14,401,000 | $1,496,744 | -$12,904,256 | 2026-02-18 |
|---|
| Q4 2025 | TVTX
TRAVERE THERAPEUTICS INC | United States | COM · Call | 214,500 | 36,600 | -177,900 | $5,126,550 | $1,398,486 | -$3,728,064 | 2026-02-18 |
|---|
| Q4 2025 | AGIO
AGIOS PHARMACEUTICALS INC | United States | COM · Call | 150,000 | 137,200 | -12,800 | $6,021,000 | $3,734,584 | -$2,286,416 | 2026-02-18 |
|---|
| Q4 2025 | SLDB
SOLID BIOSCIENCES INC | United States | COM NEW · Call | 468,000 | 424,000 | -44,000 | $2,887,560 | $2,391,360 | -$496,200 | 2026-02-18 |
|---|
| Q4 2025 | APLS
APELLIS PHARMACEUTICALS INC | United States | COM · Call | 358,000 | 325,600 | -32,400 | $8,101,540 | $8,179,072 | +$77,532 | 2026-02-18 |
|---|
| Q3 2025 | UNIQURE NV
CUSIP N90064901 | | CALL · Call | 800,000 | 535,600 | -264,400 | $11,152,000 | $31,262,972 | +$20,110,972 | 2025-11-14 |
|---|
| Q3 2025 | SLNO
SOLENO THERAPEUTICS INC | United States | COM · Put | 200,000 | 50,000 | -150,000 | $16,756,000 | $3,380,000 | -$13,376,000 | 2025-11-14 |
|---|
| Q3 2025 | CAPR
CAPRICOR THERAPEUTICS INC | United States | COM NEW · Put | 1,360,200 | 100,000 | -1,260,200 | $13,506,786 | $721,000 | -$12,785,786 | 2025-11-14 |
|---|
| Q3 2025 | RARE
ULTRAGENYX PHARMACEUTICAL IN | United States | COM · Put | 300,000 | 92,600 | -207,400 | $10,908,000 | $2,785,408 | -$8,122,592 | 2025-11-14 |
|---|
| Q3 2025 | CAPR
CAPRICOR THERAPEUTICS INC | United States | COM NEW · Call | 700,000 | 100,000 | -600,000 | $6,951,000 | $721,000 | -$6,230,000 | 2025-11-14 |
|---|
| Q3 2025 | PRAX
PRAXIS PRECISION MEDICINES I | United States | COM NEW · Call | 242,400 | 100,000 | -142,400 | $10,192,920 | $5,300,000 | -$4,892,920 | 2025-11-14 |
|---|
| Q3 2025 | SLNO
SOLENO THERAPEUTICS INC | United States | COM · Call | 200,000 | 176,100 | -23,900 | $16,756,000 | $11,904,360 | -$4,851,640 | 2025-11-14 |
|---|
| Q3 2025 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM · Call | 332,100 | 137,000 | -195,100 | $5,678,910 | $2,639,990 | -$3,038,920 | 2025-11-14 |
|---|
| Q3 2025 | CYTK
CYTOKINETICS INC | United States | COM NEW · Call | 150,000 | 110,900 | -39,100 | $4,956,000 | $6,095,064 | +$1,139,064 | 2025-11-14 |
|---|
| Q3 2025 | AKRO
AKERO THERAPEUTICS INC | United States | COM · Call | 44,400 | 41,600 | -2,800 | $2,369,184 | $1,975,168 | -$394,016 | 2025-11-14 |
|---|
| Q2 2025 | KYMR
KYMERA THERAPEUTICS INC | United States | COM · Put | 176,800 | 10,000 | -166,800 | $4,839,016 | $436,400 | -$4,402,616 | 2025-08-14 |
|---|
| Q2 2025 | SLNO
SOLENO THERAPEUTICS INC | United States | COM · Call | 243,000 | 200,000 | -43,000 | $17,362,350 | $16,756,000 | -$606,350 | 2025-08-14 |
|---|
| Q1 2025 | CLDX
CELLDEX THERAPEUTICS INC NEW | United States | COM NEW · Put | 205,500 | 17,800 | -187,700 | $5,192,985 | $323,070 | -$4,869,915 | 2025-05-15 |
|---|
| Q1 2025 | BBIO
BRIDGEBIO PHARMA INC | United States | COM · Call | 700,000 | 655,400 | -44,600 | $19,208,000 | $22,657,178 | +$3,449,178 | 2025-05-15 |
|---|
| Q1 2025 | CRVS
CORVUS PHARMACEUTICALS INC | United States | COM · Call | 754,400 | 338,100 | -416,300 | $4,036,040 | $1,075,158 | -$2,960,882 | 2025-05-15 |
|---|
| Q1 2025 | RNAM
AVIDITY BIOSCIENCES INC | United States | COM · Put | 400,000 | 300,000 | -100,000 | $11,632,000 | $8,856,000 | -$2,776,000 | 2025-05-15 |
|---|
| Q1 2025 | CRVS
CORVUS PHARMACEUTICALS INC | United States | COM · Put | 500,000 | 50,000 | -450,000 | $2,675,000 | $159,000 | -$2,516,000 | 2025-05-15 |
|---|
| Q1 2025 | SRRK
SCHOLAR ROCK HLDG CORP | United States | COM · Call | 102,100 | 100,000 | -2,100 | $4,412,762 | $3,215,000 | -$1,197,762 | 2025-05-15 |
|---|
| Q4 2024 | AMGN
AMGEN INC | United States | COM · Call | 146,000 | 74,000 | -72,000 | $47,042,660 | $19,287,360 | -$27,755,300 | 2025-02-14 |
|---|
| Q4 2024 | ANAB
ANAPTYSBIO INC | United States | COM · Put | 404,300 | 310,800 | -93,500 | $13,544,050 | $4,114,992 | -$9,429,058 | 2025-02-14 |
|---|
| Q4 2024 | ANAB
ANAPTYSBIO INC | United States | COM · Call | 350,000 | 250,000 | -100,000 | $11,725,000 | $3,310,000 | -$8,415,000 | 2025-02-14 |
|---|
| Q4 2024 | IMVT
IMMUNOVANT INC | United States | COM · Call | 500,000 | 300,000 | -200,000 | $14,255,000 | $7,431,000 | -$6,824,000 | 2025-02-14 |
|---|
| Q4 2024 | CLDX
CELLDEX THERAPEUTICS INC NEW | United States | COM NEW · Put | 305,500 | 205,500 | -100,000 | $10,383,945 | $5,192,985 | -$5,190,960 | 2025-02-14 |
|---|
| Q4 2024 | SRRK
SCHOLAR ROCK HLDG CORP | United States | COM · Call | 202,100 | 102,100 | -100,000 | $1,618,821 | $4,412,762 | +$2,793,941 | 2025-02-14 |
|---|
| Q4 2024 | SANA
SANA BIOTECHNOLOGY INC | United States | COM · Put | 650,000 | 500,000 | -150,000 | $2,704,000 | $815,000 | -$1,889,000 | 2025-02-14 |
|---|
| Q4 2024 | NMRA
NEUMORA THERAPEUTICS INC. | United States | COM · Put | 400,000 | 350,000 | -50,000 | $5,284,000 | $3,710,000 | -$1,574,000 | 2025-02-14 |
|---|
| Q4 2024 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM · Call | 200,000 | 175,100 | -24,900 | $4,550,000 | $3,356,667 | -$1,193,333 | 2025-02-14 |
|---|
| Q2 2024 | INSM
INSMED INC | United States | COM PAR $.01 · Call | 347,200 | 5,070 | -342,130 | $9,419,536 | $33,969,000 | +$24,549,464 | 2024-08-14 |
|---|
| Q2 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM · Call | 120,800 | 1,500 | -119,300 | $18,053,560 | $36,450,000 | +$18,396,440 | 2024-08-14 |
|---|
| Q2 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM · Put | 136,700 | 1,500 | -135,200 | $20,429,815 | $36,450,000 | +$16,020,185 | 2024-08-14 |
|---|
| Q2 2024 | ASTRAZENECA PLC
CUSIP 046353108 | | SPONSORED ADR · Call | 309,200 | 1,092 | -308,108 | $20,948,300 | $8,516,508 | -$12,431,792 | 2024-08-14 |
|---|
| Q2 2024 | PRAX
PRAXIS PRECISION MEDICINES I | United States | COM NEW · Call | 21,800 | 3,000 | -18,800 | $1,330,236 | $12,408,000 | +$11,077,764 | 2024-08-14 |
|---|
| Q2 2024 | BBIO
BRIDGEBIO PHARMA INC | United States | COM · Call | 389,400 | 6,000 | -383,400 | $12,040,248 | $15,198,000 | +$3,157,752 | 2024-08-14 |
|---|
| Q2 2024 | INSM
INSMED INC | United States | COM PAR $.01 · Put | 70,900 | 709 | -70,191 | $1,923,517 | $4,750,300 | +$2,826,783 | 2024-08-14 |
|---|
| Q2 2024 | ANVS
ANNOVIS BIO INC | United States | COM · Call | 250,000 | 517 | -249,483 | $2,975,000 | $297,792 | -$2,677,208 | 2024-08-14 |
|---|
| Q2 2024 | AMGN
AMGEN INC | United States | COM · Call | 60,000 | 600 | -59,400 | $17,059,200 | $18,747,000 | +$1,687,800 | 2024-08-14 |
|---|
| Q2 2024 | CORT
CORCEPT THERAPEUTICS INC | United States | COM · Call | 279,500 | 1,860 | -277,640 | $7,040,605 | $6,043,140 | -$997,465 | 2024-08-14 |
|---|
| Q2 2024 | ARE
ALEXANDRIA REAL ESTATE EQ IN | United States | COM · Put | 73,300 | 733 | -72,567 | $9,449,103 | $8,573,901 | -$875,202 | 2024-08-14 |
|---|
| Q2 2024 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM · Call | 116,100 | 1,000 | -115,100 | $15,030,306 | $15,800,000 | +$769,694 | 2024-08-14 |
|---|
| Q2 2024 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM · Put | 178,900 | 2,789 | -176,111 | $3,132,539 | $3,628,489 | +$495,950 | 2024-08-14 |
|---|
| Q2 2024 | ABEO
ABEONA THERAPEUTICS INC | United States | COM NEW · Call | 67,500 | 171 | -67,329 | $489,375 | $72,504 | -$416,871 | 2024-08-14 |
|---|
| Q2 2024 | ANVS
ANNOVIS BIO INC | United States | COM · Put | 251,900 | 5,517 | -246,383 | $2,997,610 | $3,177,792 | +$180,182 | 2024-08-14 |
|---|
| Q2 2024 | RAPT THERAPEUTICS INC
CUSIP 75382E109 | United States | COM · Call | 87,200 | 2,000 | -85,200 | $783,056 | $610,000 | -$173,056 | 2024-08-14 |
|---|
| Q1 2024 | AMLX
AMYLYX PHARMACEUTICALS INC | United States | COM · Call | 1,298,400 | 1,060,100 | -238,300 | $19,112,448 | $3,010,684 | -$16,101,764 | 2024-05-17 |
|---|
| Q1 2024 | KRYS
KRYSTAL BIOTECH INC | United States | COM · Put | 412,000 | 375,000 | -37,000 | $51,112,720 | $66,723,750 | +$15,611,030 | 2024-05-17 |
|---|
| Q1 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM · Call | 169,700 | 120,800 | -48,900 | $32,482,277 | $18,053,560 | -$14,428,717 | 2024-05-17 |
|---|
| Q1 2024 | LNTH
LANTHEUS HLDGS INC | United States | COM · Call | 270,000 | 170,000 | -100,000 | $16,740,000 | $10,580,800 | -$6,159,200 | 2024-05-17 |
|---|
| Q1 2024 | BMEA
BIOMEA FUSION INC | United States | COM · Put | 500,000 | 103,000 | -397,000 | $7,260,000 | $1,539,850 | -$5,720,150 | 2024-05-17 |
|---|
| Q1 2024 | EYPT
EYEPOINT PHARMACEUTICALS INC | United States | COM NEW · Call | 391,000 | 206,500 | -184,500 | $9,036,010 | $4,268,355 | -$4,767,655 | 2024-05-17 |
|---|
| Q1 2024 | MLTX
MOONLAKE IMMUNOTHERAPEUTICS | Switzerland | CLASS A ORD · Put | 200,600 | 158,000 | -42,600 | $12,114,234 | $7,936,340 | -$4,177,894 | 2024-05-17 |
|---|
| Q1 2024 | CRNX
CRINETICS PHARMACEUTICALS IN | United States | COM · Call | 100,000 | 8,700 | -91,300 | $3,558,000 | $407,247 | -$3,150,753 | 2024-05-17 |
|---|
| Q1 2024 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM · Call | 182,600 | 116,100 | -66,500 | $17,608,118 | $15,030,306 | -$2,577,812 | 2024-05-17 |
|---|